John E. Prime
YOU?
Author Swipe
View article: Supplementary Figures 1 through 5, Supplementary Tables 1 through 4, and Supplementary Methods from Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
Supplementary Figures 1 through 5, Supplementary Tables 1 through 4, and Supplementary Methods from Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery Open
Supplementary Figure S1: Summary of experiments Supplementary Figure S2: Gating strategy Supplementary Figure S3:Profiling by array CGH, whole-exome and targeted sequencing Supplementary Figure S4: Comparison of mutational profiles of muri…
View article: Supplementary Figures 1 through 5, Supplementary Tables 1 through 4, and Supplementary Methods from Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
Supplementary Figures 1 through 5, Supplementary Tables 1 through 4, and Supplementary Methods from Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery Open
Supplementary Figure S1: Summary of experiments Supplementary Figure S2: Gating strategy Supplementary Figure S3:Profiling by array CGH, whole-exome and targeted sequencing Supplementary Figure S4: Comparison of mutational profiles of muri…
View article: Data from Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
Data from Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery Open
Murine syngeneic tumor models are critical to novel immuno-based therapy development, but the molecular and immunologic features of these models are still not clearly defined. The translational relevance of differences between the models i…
View article: Data from Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
Data from Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery Open
Murine syngeneic tumor models are critical to novel immuno-based therapy development, but the molecular and immunologic features of these models are still not clearly defined. The translational relevance of differences between the models i…
View article: Supplementary Dataset from Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
Supplementary Dataset from Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery Open
Supplementary dataset containing raw data from targeted sequencing, whole exome sequencing, array CGH and transcriptomic analysis
View article: Supplementary Dataset from Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
Supplementary Dataset from Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery Open
Supplementary dataset containing raw data from targeted sequencing, whole exome sequencing, array CGH and transcriptomic analysis